BOSTON and LONDON, November 8, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies …
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
BOSTON and LONDON, October 14, 2024 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company …
NOTICE & RESULTS OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON THURSDAY, NOVEMBER 7, 2024
RESULTS OF GENERAL MEETING OF SHAREHOLDERS - NOVEMBER 7, 2024 NOTICE OF GENERAL MEETING OF SHAREHOLDERS - NOVEMBER 7, 2024 GENERAL MEETING FORM OF PROXY …
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
BOSTON and LONDON, September 17, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced …
[Read more...] about Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
Akari Therapeutics Reports Second Quarter – 2024 Financial Results and Recent Highlights
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio’s …
